Evidence map›Paper›PMID 36611269›Full record

ArticleThe Journal of infectious diseases2023

Development of a Corticosteroid-Immunosuppressed Mouse Model to Study the Pathogenesis and Therapy of Influenza-Associated Pulmonary Aspergillosis.

Sebastian Wurster, Jezreel Pantaleón García, Nathaniel D Albert, Ying Jiang, Keerthi Bhoda, Vikram V Kulkarni, Yongxing Wang, Thomas J Walsh, Scott Evans, Dimitrios P Kontoyiannis

Open access · greenAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Current issues in molecular biology · 2026
    Article
  6. Diagnostic performance ofJournal of thoracic disease · 2025
    Article
  7. Review
  8. Review
  9. Article
  10. Recent developments inMicrobiology and molecular biology reviews : MMBR · 2025
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Sebastian WursterDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-7784-7256
Jezreel Pantaleón GarcíaDepartment of Pulmonary Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Nathaniel D AlbertDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Ying JiangDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Keerthi BhodaDepartment of Pulmonary Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Vikram V KulkarniDepartment of Pulmonary Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Yongxing WangDepartment of Pulmonary Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Thomas J WalshCenter for Innovative Therapeutics and Diagnostics, Richmond, Virginia, USA.
Scott EvansDepartment of Pulmonary Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0003-4503-0644
Dimitrios P KontoyiannisDepartment of Infectious Diseases, Infection Control and Employee Health, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
The University of Texas MD Anderson Cancer Center · USInnovative Clinical Research · US

Funding

Inducible epithelial resistance: a program investigating mechanisms to protect against acute and chronic complications of pneumoniaR35HL144805 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EVANS, SCOTT E. · 2019 to 2025
$6.2M
Epithelial mechanisms of inducible resistance to AML-associated pneumoniaR01HL117976 · NHLBI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI EVANS, SCOTT E. · 2014 to 2018
$2.0M
NHLBI NIH HHS R01 HL117976NHLBI NIH HHS R35 HL144805NIH HHS R35 HL144805
6 · The paper itself

Abstract

Influenza-associated pulmonary aspergillosis (IAPA) is a feared complication in patients with influenza tracheobronchitis, especially those receiving corticosteroids. Herein, we established a novel IAPA mouse model with low-inoculum Aspergillus infection and compared outcomes in mice with and without cortisone acetate (CA) immunosuppression. CA was an independent predictor of increased morbidity/mortality in mice with IAPA. Early antifungal treatment with liposomal amphotericin B was pivotal to improve IAPA outcomes in CA-immunosuppressed mice, even after prior antiviral therapy with oseltamivir. In summary, our model recapitulates key clinical features of IAPA and provides a robust preclinical platform to study the pathogenesis and treatment of IAPA.

Indexed as

AspergillosisInfluenza, HumanPulmonary AspergillosisAdrenal Cortex HormonesAnimalsAntifungal AgentsAspergillus fumigatusHumansMiceAdrenal Cortex HormonesAntifungal Agentsamphotericin Baspergillosiscorticosteroidsinfluenzamouse modeloseltamivirpneumonia

Identifiers

PMID36611269
PMCPMC10319956
OpenAlexW4313706708

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.